|
1
|
Burningham Z, Hashibe M, Spector L and
Schiffman JD: The epidemiology of sarcoma. Clin Sarcoma Res.
2:142012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stiller CA, Trama A, Serraino D, Rossi S,
Navarro C, Chirlaque MD and Casali PG; RARECARE Working Group, :
Descriptive epidemiology of sarcomas in Europe: Report from the
RARECARE project. Eur J Cancer. 49:684–695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization (WHO), . Soft
Tissue and Bone Tumours. WHO Classification of Tumours. 5th
edition. Vol 3. IARC; Lyon: 2020, https://publications.iarc.fr/588
|
|
4
|
Gatta G, Capocaccia R, Botta L, Mallone S,
De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK,
Siesling S, et al: Burden and centralized treatment in Europe of
rare tumors: Results of RARECAREnet-a population-based study.
Lancet Oncol. 18:1022–1039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(NCCN), . Bone Cancer (ver. 2.2021). http://www.nccn.org/professionals/physician_gls/pdf/bone.pdfJuly
26–2021
|
|
8
|
National Comprehensive Cancer Network
(NCCN), . Soft Tissue Sarcoma (ver. 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdfJuly
26–2021
|
|
9
|
Gronchi A, Miah AB, Dei Tos AP, Abecassis
N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, et al
ESMO Guidelines Committee EURACAN and GENTURIS, : Soft tissue and
visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
32:1348–1365. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Casali PG, Bielack S, Abecassis N, Aro HT,
Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan
B, et al ESMO Guidelines Committee, PaedCan and ERN EURACAN, : Bone
sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Oncol. 29 (Suppl 4):iv79–iv95.
2018.PubMed/NCBI
|
|
11
|
Rettew AN, Getty PJ and Greenfield EM:
Receptor tyrosine kinases in osteosarcoma: Not just the usual
suspects. Adv Exp Med Biol. 804:47–66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu P, Nielsen TE and Clausen MH:
FDA-approved small-molecule kinase inhibitors. Trends Pharmacol
Sci. 36:422–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamberg P, Verweij J and Sleijfer S:
(Pre)clinical pharmacology and activity of pazopanib, a novel
multikinase angiogenesis inhibitor. Oncologist. 15:539–547. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van der Graaf WTA, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib formetastatic soft-tissue sarcoma
(PALETTE): A randomized, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mir O, Brodowicz T, Italiano A, Wallet J,
Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas
S, et al: Safety and efficacy of regorafenib in patients with
advanced soft tissue sarcoma (REGOSARC): A randomized,
double-blind, placebo-controlled, phase 2 trial. Lancet Oncol.
17:1732–1742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duffaud F, Mir O, Boudou-Rouquette P,
Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E,
Italiano A, Collard O, et al: Efficacy and safety of regorafenib in
adult patients with metastatic osteosarcoma: A noncomparative,
randomized, double-blind, placebo-controlled, phase 2 study. Lancet
Oncol. 20:120–133. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davis LE, Bolejack V, Ryan CW, Ganjoo KN,
Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, et
al: Randomized double-blind phase II study of regorafenib in
patients with metastatic osteosarcoma. J Clin Oncol. 37:1424–1431.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Attia S, Bolejack V, Ganjoo KN, George S,
Agulnik M, Rushing DA, Loggers ET, Livingston MB, Wright JA, Chawla
SP, et al: A phase 2 trial of regorafenib (REGO) in patients with
advanced Ewing sarcoma and related tumors of soft tissue and bone:
SARC0024 trial results. J Clin Oncol. 35 (Suppl 15):S110052017.
View Article : Google Scholar
|
|
19
|
Judson I, Morden JP, Kilburn L, Leahy M,
Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L,
et al: Cediranib in patients with alveolar softpart sarcoma
(CASPS): A double-blind, placebo-controlled, randomized, phase 2
trial. Lancet Oncol. 20:1023–1034. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schöffski P, Toulmonde M, Estival A,
Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de
Haan J, Wozniak A, et al: Randomized phase 2 study comparing the
efficacy and safety of the oral tyrosine kinase inhibitor
nintedanib with single agent ifosfamide in patients with advanced,
inoperable, metastatic soft tissue sarcoma after failure of
first-line chemotherapy: EORTC-1506-STBSG ‘ANITA’. Eur J Cancer.
152:26–40. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Benson C, Ray-Coquard I, Sleijfer S,
Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P,
Chawla S, et al: Outcome of uterine sarcoma patients treated with
pazopanib: A retrospective analysis based on two European
organisation for research and treatment of cancer (EORTC) soft
tissue and bone sarcoma group (STBSG) clinical trials 62043 and
62072. Gynecol Oncol. 142:89–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kollár A, Jones RL, Stacchiotti S,
Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D,
Duffaud F, et al: Pazopanib in advanced vascular sarcomas: An EORTC
soft tissue and bone sarcoma group (STBSG) retrospective analysis.
Acta Oncol. 56:88–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gelderblom H, Judson IR, Benson C,
Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra
M, Mungul A, et al: Treatment patterns and clinical outcomes with
pazopanib in patients with advanced soft tissue sarcomas in a
compassionate use setting: Results of the SPIRE study. Acta Oncol.
56:1769–1775. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
ElNaggar AC, Hays JL and Chen JL: Addition
of everolimus post VEGFR inhibition treatment failure in advanced
sarcoma patients who previously benefited from VEGFR inhibition: A
case series. PLoS One. 11:e01569852016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katz D, Azraq Y, Eleyan F, Gill S, Peretz
T and Merimsky O: Pazolimus: Pazopanib plus sirolimus following
progression on pazopanib, a retrospective case series analysis. BMC
Cancer. 16:6162016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dembla V, Groisberg R, Hess K, Fu S,
Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, et al:
Outcomes of patients with sarcoma enrolled in clinical trials of
pazopanib combined with histone deacetylase, mTOR, Her2, or MEK
inhibitors. Sci Rep. 7:159632017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu B, Li J, Xie Q, Diao L, Gai L and Yang
W: Efficacy and safety of apatinib monotherapy in advanced bone and
soft tissue sarcoma: An observational study. Cancer Biol Ther.
19:198–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie L, Xu J, Sun X, Li X, Liu K, Liang X,
Zhou Z, Zhuang H, Sun K, Wu Y, et al: Apatinib plus ifosfamide and
etoposide for relapsed or refractory osteosarcoma: A retrospective
study in two centers. Oncol Lett. 22:5522021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie L, Guo W, Wang Y, Yan T, Ji T and Xu
J: Apatinib for advanced sarcoma: Results from multiple
institutions' off-label use in China. BMC Cancer. 18:3962018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stacchiotti S, Negri T, Libertini M,
Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi
C, Messina A, et al: Sunitinib malate in solitary fibrous tumor
(SFT). Ann Oncol. 23:3171–3179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stacchiotti S, Pantaleo MA, Astolfi A,
Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A,
Colombo C, et al: Activity of sunitinib in extraskeletal myxoid
chondrosarcoma. Eur J Cancer. 50:1657–1664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang HY, Chu JF, Zhang P, Wang JQ, Yan Z,
Yao SN, Yao ZH and Liu YY: Safety and efficacy of chemotherapy
combined with anlotinib plus anlotinib maintenance in Chinese
patients with advanced/metastatic soft tissue sarcoma. Onco Targets
Ther. 13:1561–1568. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hindi N, Casali PG, Morosi C, Messina A,
Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A and
Stacchiotti S: Imatinib in advanced chordoma: A retrospective case
series analysis. Eur J Cancer. 51:2609–2614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smolle MA, Szkandera J, Andreou D,
Palmerini E, Bergovec M and Leithner A: Treatment options in
unresectable soft tissue and bone sarcoma of the extremities and
pelvis-a systematic literature review. EFORT Open Rev. 5:799–814.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Constantinidou A, Pollack S, Loggers E,
Rodler E and Jones RL: The evolution of systemic therapy in
sarcoma. Expert Rev Anticancer Ther. 13:211–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Polychronidou G, Karavasilis V, Pollack
SM, Huang PH, Lee A and Jones RL: Novel therapeutic approaches in
chondrosarcoma. Future Oncol. 13:637–648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bailey K, Cost C, Davis I, Glade-Bender J,
Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, et
al: Emerging novel agents for patients with advanced Ewing sarcoma:
A report from the Children's Oncology Group (COG) New Agents for
Ewing Sarcoma Task Force. F1000Res. 8:F1000Faculty Rev. –493. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakano K and Takahash S: current molecular
targeted therapies for bone and soft tissue sarcomas. Int J Mol
Sci. 19:7392018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sleijfer S, Ray-Coquard I, Papai Z, Le
Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De
Brauwer A, et al: Pazopanib, a multikinase angiogenesis inhibitor,
in patients with relapsed or refractory advanced soft tissue
sarcoma: A phase II study from the European organization for
research and treatment of cancer-soft tissue and bone sarcoma group
(EORTC Study 62043). J Clin Oncol. 27:3126–3132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, Wozniak A, Sciot R, Cornillie J,
Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter
M and Schöffski P: Pazopanib, a receptor tyrosine kinase inhibitor,
suppresses tumor growth through angiogenesis in dedifferentiated
liposarcoma xenograft models. Transl Oncol. 7:665–671. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Samuel BL, Chawla SP, Somaiah N, Staddon
AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA,
Walker MS and Stepanski EJ: Results of a prospective phase 2 study
of pazopanib in patients with advanced intermediate-grade or
high-grade liposarcoma. Cancer. 123:4640–4647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chow W, Frankel P, Ruel C, Araujo DM,
Milhem M, Okuno S, Hartner L, Undevia S and Staddon A: Results of a
prospective phase 2 study of pazopanib in patients with surgically
unresectable or metastatic chondrosarcoma. Cancer. 126:105–111.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lipplaa A, Dijkstra S and Gelderblom H:
Efficacy of pazopanib and sunitinib in advanced axial chordoma: A
single reference centre case series. Clin Sarcoma Res. 6:192016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Keir ST, Morton CL, Wu J, Kurmasheva RT,
Houghton PJ and Smith MA: Initial testing of the multitargeted
kinase inhibitor pazopanib by the pediatric preclinical testing
program. Pediatr Blood Cancer. 59:586–588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Umeda K, Kato I, Saida S, Okamoto T and
Adachi S: Pazopanib for second recurrence of osteosarcoma in
pediatric patients. Pediatr Int. 59:937–938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu X, Xu J, Li F, Liao Z, Ren Z, Zhu L,
Shi Y, Zhao G, Bai X, Zhao J, et al: Efficacy and safety of the
VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma:
Chinese cohort data from NCT03121846. Biomed Pharmacother.
122:1095872020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xie L, Xu J, Sun X, Tang X, Yan T, Yang R
and Guo W: Apatinib for advanced osteosarcoma after failure of
standard multimodal therapy: An open label phase II clinical trial.
Oncologist. 24:e542–e550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zheng B, Ren T, Huang Y and Guo W:
Apatinib inhibits migration and invasion as well as PD-L1
expression in osteosarcoma by targeting STAT3. Biochem Biophys Res
Commun. 495:1695–1701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li F, Liao Z, Zhang C, Zhao J, Xing R,
Teng S, Zhang J, Yang Y and Yang J: Apatinib as targeted therapy
for sarcoma. Oncotarget. 9:24548–24560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xie L, Xu J, Sun X, Guo W, Gu J, Liu K,
Zheng B, Ren T, Huang Y, Tang X, et al: Apatinib plus camrelizumab
(anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO)
progressing after chemotherapy: A single-arm, open-label, phase 2
trial. J Immunother Cancer. 8:e0007982020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chow LQ and Eckhardt SG: Sunitinib: From
rational design to clinical efficacy. J Clin Oncol. 25:884–896.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
George S, Merriam P, Maki RG, Van den
Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM,
D'Adamo DR, et al: Multicenter phase II trial of sunitinib in the
treatment of nongastrointestinal stromal tumor sarcomas. J Clin
Oncol. 27:3154–3160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mahmood ST, Agresta S, Vigil CE, Zhao X,
Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, et al:
Phase II study of sunitinib malate, a multitargeted tyrosine kinase
inhibitor in patients with relapsed or refractory soft tissue
sarcomas. Focus on three prevalent histologies: Leiomyosarcoma,
liposarcoma and malignant fibrous histiocytoma. Int J Cancer.
129:1963–1969. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jo JC, Hong YS, Kim KP, Lee JL, Lee J,
Park YS, Kim SY, Ryu JS, Lee JS and Kim TW: A prospective
multicenter phase II study of sunitinib in patients with advanced
aggressive fibromatosis. Invest New Drugs. 32:369–376. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jagodzińska-Mucha P, Świtaj T, Kozak K,
Koseła-Paterczyk H, Klimczak A, Ługowska I, Rogala P, Wągrodzki M,
Falkowski S and Rutkowski P: Long-term results of therapy with
sunitinib in metastatic alveolar soft part sarcoma. Tumori.
103:231–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Martin-Broto J, Hindi N, Grignani G,
Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S,
Lopez-Pousa A, D'Ambrosio L, Gutierrez A, et al: Nivolumab and
sunitinib combination in advanced soft tissue sarcomas: A
multicenter, single-arm, phase Ib/II trial. J Immunother Cancer.
8:e0015612020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Palmerini E, Lopez-Pousa A, Grignani G,
Redondo A, Hindi N, Stacchiotti S, Sebio A, Lopez-Martin JA,
Morales CMV, Martinez-Trufero J, et al: IMMUNOSARC: A collaborative
Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of
sunitinib and nivolumab in advanced soft tissue and bone sarcoma:
Results from the phase II part, bone sarcoma cohort. J Clin Oncol.
38 (Suppl 15):Se115222020. View Article : Google Scholar
|
|
59
|
Mross K, Frost A, Steinbild S, Hedbom S,
Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O and
Christensen O: A phase I dose-escalation study of regorafenib (BAY
73-4506), an inhibitor of oncogenic, angiogenic, and stromal
kinases, in patients with advanced solid tumors. Clin Cancer Res.
18:2658–2667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Berry V, Basson L, Bogart E, Mir O, Blay
JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S,
Liegl-Antzager B, et al: REGOSARC: Regorafenib versus placebo in
doxorubicin-refractory soft-tissue sarcoma-A Quality-adjusted time
without symptoms of progression or toxicity analysis. Cancer.
123:2294–2302. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Marrari A, Bertuzzi A, Bozzarelli S,
Gennaro N, Giordano L, Quagliuolo V, De Sanctis R, Sala S,
Balzarini L and Santoro A: Activity of regorafenib in advanced
pretreated soft tissue sarcoma: Results of a single-center phase II
study. Medicine (Baltimore). 99:e207192020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Santoro A, Comandone A, Basso U, Soto
Parra H, De Sanctis R, Stroppa E, Marcon I, Giordano L, Lutman FR,
Boglione A and Bertuzzi A: Phase II prospective study with
sorafenib in advanced soft tissue sarcomas after
anthracycline-based therapy. Ann Oncol. 24:1093–1098. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Valentin T, Fournier C, Penel N, Bompas E,
Chaigneau L, Isambert N and Chevreau C: Sorafenib in patients with
progressive malignant solitary fibrous tumors: A subgroup analysis
from a phase II study of the French Sarcoma Group (GSF/GETO).
Invest New Drugs. 31:1626–1627. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
von Mehren M, Rankin C, Goldblum JR,
Demetri GD, Bramwell V, Ryan CW and Borden E: Phase 2 Southwest
Oncology Group-directed intergroup trial (S0505) of sorafenib in
advanced soft tissue sarcomas. Cancer. 118:770–776. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: An Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for
patients with unresectable high-grade osteosarcoma progressing
after standard treatment: A nonrandomized phase 2 clinical trial.
Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schöffski P, Blay JY and Ray-Coquard I:
Cabozantinib as an emerging treatment for sarcoma. Curr Opin Oncol.
32:321–331. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ikeda S, Kudoh K, Sasaki N, Takano M, Goto
T, Sakamoto RK, Kita T, Susumu N, Aoki D, Kouta H and Kikuchi Y:
Synergistic effects of cabozantinib to temozolomide and bevacizumab
in patients with heavily pretreated relapsed uterine
leiomyosarcoma. J Clin Oncol. 33 (15_Suppl):S55902015. View Article : Google Scholar
|
|
69
|
Italiano A, Mir O, Mathoulin-Pelissier S,
Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F,
Entz-Werlé N, Saada E, et al: Cabozantinib in patients with
advanced Ewing sarcoma or osteosarcoma (CABONE): A multicenter,
single-arm, phase 2 trial. Lancet Oncol. 21:446–455. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Morabito A, De Maio E, Di Maio M, Normanno
N and Perrone F: Tyrosine kinase inhibitors of vascular endothelial
growth factor receptors in clinical trials: Current status and
future directions. Oncologist. 11:753–764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Brahmi M, Vanacker H and Dufresne A: Novel
therapeutic options for alveolar soft part sarcoma: Antiangiogenic
therapy, immunotherapy and beyond. Curr Opin Oncol. 32:295–300.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fox E, Aplenc R, Bagatell R, Chuk MK,
Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N,
Marotti M, et al: A phase 1 trial and pharmacokinetic study of
cediranib, an orally bioavailable pan-vascular endothelial growth
factor receptor inhibitor, in children and adolescents with
refractory solid tumors. J Clin Oncol. 28:5174–5181. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cohen JW, Widemann BC, Derdak J, Dombi E,
Goodwin A, Dompierre J, Onukwubiri U, Steinberg SM, O'Sullivan
Coyne G, Kummar S, et al: Cediranib phase-II study in children with
metastatic alveolar soft-part sarcoma (ASPS). Pediatr Blood Cancer.
66:e279872019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schöffski P, Wozniak A, Stacchiotti S,
Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud
F, Richter S, et al: Activity and safety of crizotinib in patients
with advanced clear-cell sarcoma with MET alterations: European
organization for research and treatment of cancer phase II trial
90101 ‘CREATE’. Ann Oncol. 28:3000–3008. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Schöffski P, Wozniak A, Kasper B, Aamdal
S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A,
Lindner LH, et al: Activity and safety of crizotinib in patients
with alveolar soft part sarcoma with rearrangement of TFE3:
European organization for research and treatment of cancer (EORTC)
phase II trial 90101 ‘CREATE’. Ann Oncol. 29:758–765. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Schöffski P, Wozniak A, Leahy MG, Aamdal
S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M,
Sciot R, et al: The tyrosine kinase inhibitor crizotinib does not
have clinically meaningful activity in heavily pre-treated patients
with advanced alveolar rhabdomyosarcoma with FOXO rearrangement:
European Organisation for Research and Treatment of Cancer phase 2
trial 90101 ‘CREATE’. Eur J Cancer. 94:156–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Schöffski P, Sufliarsky J, Gelderblom H,
Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy
MG, Italiano A, et al: Crizotinib in patients with advanced,
inoperable inflammatory myofibroblastic tumours with and without
anaplastic lymphoma kinase gene alterations (European Organisation
for Research and Treatment of Cancer 90101 CREATE): A multicentre,
single-drug, prospective, non-randomised phase 2 trial. Lancet
Respir Med. 6:431–441. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Geller JI, Fox E, Turpin BK, Goldstein SL,
Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL and Weigel BJ: A
study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in
children and adolescents with recurrent or refractory solid tumors:
A children's oncology group phase 1 and pilot consortium trial
(ADVL1315). Cancer. 124:4548–4555. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wilky BA, Trucco MM, Subhawong TK, Florou
V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, et
al: Axitinib plus pembrolizumab in patients with advanced sarcomas
including alveolar soft-part sarcoma: A single-center, single-arm,
phase 2 trial. Lancet Oncol. 20:837–848. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li
L, Wang F, Hao Y, Li C and Chi Y: Safety, Pharmacokinetics, and
antitumor properties of anlotinib, an oral multitarget tyrosine
kinase inhibitor, in patients with advanced refractory solid
tumors. J Hematol Oncol. 9:1052016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang
G, Du F, Sun Y, Wu Q, Qu G, et al: Safety and efficacy of
anlotinib, a multikinase angiogenesis inhibitor, in patients with
refractory metastatic soft-tissue sarcoma. Clin Cancer Res.
24:5233–5238. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tang L, Wang Y, Zhang J, Yu W, Huang Y and
Yao Y: Efficacy and safety of anlotinib in advanced soft tissue
sarcoma: Results from one of multi-centers in a phase IIB trial
(ALTER0203). J Clin Oncol. 37 (Suppl 15):e225182019. View Article : Google Scholar
|
|
83
|
Pindolia VK and Zarowitz BJ: Imatinib
mesylate, the first molecularly targeted gene suppressor.
Pharmacotherapy. 22:1249–1265. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chugh R, Wathen JK, Maki RG, Benjamin RS,
Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML,
et al: Phase II multicenter trial of imatinib in 10 histologic
subtypes of sarcoma using a bayesian hierarchical statistical
model. J Clin Oncol. 27:3148–3153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Stacchiotti S, Longhi A, Ferraresi V,
Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti
S, Messina A, et al: Phase II study of imatinib in advanced
chordoma. J Clin Oncol. 30:914–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bond M, Bernstein ML, Pappo A, Schultz KR,
Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib
mesylate in children with refractory or relapsed solid tumors: A
Children's oncology group study. Pediatr Blood Cancer. 50:254–258.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jakacki RI, Hamilton M, Gilbertson RJ,
Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE and
Adamson PC: Pediatric phase I and pharmacokinetic study of
erlotinib followed by the combination of erlotinib and
temozolomide: A Children's oncology group phase I consortium study.
J Clin Oncol. 26:4921–4927. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ray-Coquard I, Le Cesne A, Whelan JS,
Schoffski P, Bui BN, Verweij J, Marreaud S, van Glabbeke M,
Hogendoorn P and Blay JY: A phase II study of gefitinib for
patients with advanced HER-1 expressing synovial sarcoma refractory
to doxorubicin-containing regimens. Oncologist. 13:467–473. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Brennan RC, Furman W, Mao S, Wu J, Turner
DC, Stewart CF, Santana V and McGregor LM: Phase I dose escalation
and pharmacokinetic study of oral gefitinib and irinotecan in
children with refractory solid tumors. Cancer Chemother. Pharmacol.
74:1191–1198. 2014.PubMed/NCBI
|
|
90
|
Chen TWC, Yu CW, Hong RL, Yen CC, Guo JC,
Chen SC, Lee JC, Chen ML, Chang HF, Hsu MC and Kung TF: An Ib/II
study of the combination of lenvatinib (L) and eribulin (E) in
advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER). J
Clin Oncol. 38 (15 _Suppl):S115072020. View Article : Google Scholar
|
|
91
|
Judson I, Verweij J, Gelderblom H,
Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan
J, Hohenberger P, et al: Doxorubicin alone versus intensified
doxorubicin plus ifosfamide for first-line treatment of advanced or
metastatic soft-tissue sarcoma: A randomized controlled phase 3
trial. Lancet Oncol. 15:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kantidakis G, Litière S, Neven A, Vinches
M, Judson I, Schöffski P, Wardelmann E, Stacchiotti S, D'Ambrosio
L, Marréaud S, et al: Efficacy thresholds for clinical trials with
advanced or metastatic leiomyosarcoma patients: A European
organization for research and treatment of cancer soft tissue and
bone sarcoma group meta-analysis based on a literature review for
soft-tissue sarcomas. Eur J Cancer. 154:253–268. 2021. View Article : Google Scholar : PubMed/NCBI
|
